Billionaire Steve Cohen's 10 Small-Cap Stock Picks with Huge Upside Potential
Known for speed, agility, and a high-risk, high-reward investment approach, Steve Cohen is one of the most successful hedge fund managers on Wall Street.
Nurix Therapeutics Inc. (NRIX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 6,057,024 | $55,966,902 | -1% | 1.56% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 3,882,125 | $35,870,835 | 0.26% | |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 3,780,055 | $34,927,708 | -5% | 1.71% |
| 4. | Redmile Group Jeremy Green | 3,678,394 | $33,988,361 | -2% | 3.31% |
| 5. | Vestal Point Capital Ryan Wilder | 3,475,000 | $32,109,000 | +74% | 1.45% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.07 | 37,600 | $641,696.64 | 50,897 | 2025-11-24 | Filing | |
| $12.56 | 6,284 | $78,931.44 | 37,592 | 2025-11-03 | Filing | |
| $12.80 | 3,130 | $40,053.67 | 43,876 | 2025-10-30 | Filing | |
| $12.80 | 3,644 | $46,631.17 | 50,897 | 2025-10-30 | Filing | |
| $12.80 | 4,087 | $52,300.11 | 76,751 | 2025-10-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,887,537 | $82,120,843 | 0% | |
| 2. | 6,762,586 | $62,486,295 | 0% | |
| 3. | 4,488,776 | $41,476,290 | 0% | |
| 4. | 2,862,387 | $26,448,456 | 0% | |
| 5. | 2,260,746 | $20,889,301 | 0% |
News See All
Stifel Maintains Buy Rating on Nurix (NRIX) Stock
On June 3, Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics, Inc. (NASDAQ:NRIX) with a price target of $35.
10 Best Low Priced Biotech Stocks to Buy Now
On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low valuations...
10 Worst ARK Stocks To Buy According to Short Sellers
Cathie Wood of ARK Investment is one of Wall Street's most well-known hedge fund bosses.
10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance.
10 Best Small-Cap Healthcare Stocks To Buy Now
In difficult economic times, healthcare equities are sometimes regarded as a defensive investment.
11 Cheap Small-Cap Stocks to Buy Before the Next Breakout
In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout.
Cathie Wood is Buying These 10 Growth Stocks
In this article, we discuss the 10 growth stocks that Cathie Wood is buying.
Harvard University's Latest Portfolio: 10 Best Biotech Stock Picks
In this article, we will look at Harvard University's latest stock portfolio and list its 10 best biotech stock picks.
Cathie Wood's 10 Favorite Stock Picks for the Rest of 2022
In this article, we discuss Cathie Wood’s 10 favorite stock picks for the rest of 2022.